Please login to the form below

Not currently logged in
Email:
Password:

Benlysta

This page shows the latest Benlysta news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

It is however growing at a much faster rate; respiratory grew 3%, HIV was up 11% and immuno-inflammation – led by lupus drug Benlysta (belimumab) – rose 28%.

Latest news

  • AstraZeneca’s Lupus treatment misses mark in trial AstraZeneca’s Lupus treatment misses mark in trial

    The candidate in question operates a differently to other lupus treatments, including already approved Benlysta, GlaxoSmithKline’s subcutaneous formulation of its market-leading product. ... However, anifrolumab targets a protein that is involved in

  • GSK closes in on EU approval for triple COPD therapy GSK closes in on EU approval for triple COPD therapy

    The CHMP also delivered more good news to GSK by recommending approval of the company's subcutaneous pen-injector of Benlysta (belimumab), providing a more patient-friendly alternative to the current ... Benlysta is used as an add-on treatment for adults

  • GSK and AZ drugs impress in lupus trials GSK and AZ drugs impress in lupus trials

    GSK reported new phase III data on a new subcutaneous formulation of its market-leading Benlysta (belimumab) product - which was approved as in one-hour infusion formulation for SLE in 2011, ... Benlysta sales were £166m ($251m) in the first nine months

  • Hints of recovery at GSK as group sales climb Hints of recovery at GSK as group sales climb

    Some of its newer treatments have also failed to grow as expected, with the much-hyped lupus drug Benlysta (belimumab) - the first drug approved for the condition in fifty years - failing

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    Other gainers included platelet-booster Promacta (eltrombopag) - up 46 per cent to £186m in 2013 - and lupus treatment Benlysta (belimumab), which more than doubled to £146m.

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics